Helicos Secures Bridge Loan, Abandons Plans for CLIA Lab as Cash Position Weakens, Revenues Fall | GenomeWeb

By Bernadette Toner

This article has been updated from a previous version, published Nov. 18, to reflect the fact that Helicos has filed its quarterly earnings report and disclosed other financial information.

Helicos BioSciences has entered into a bridge loan agreement worth up to $4 million with two investors in order to shore up its cash holdings in the face of dwindling resources.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.